NCT04552197View on ClinicalTrials.gov

A Study of JNJ-64251330 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

December 29, 2020

Study Completion Date

December 29, 2020

Conditions
Healthy
Interventions
DRUG

JNJ-64251330

JNJ-64251330 tablet will be administered orally.

DRUG

Tofacitinib

Tofacitinib tablets will be administered orally.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04552197 - A Study of JNJ-64251330 in Healthy Participants | Biotech Hunter | Biotech Hunter